Incyte Corporation

Incyte Holdings Corporation

Prelude Therapeutics Incorporated

Bristol-myers Squibb Compnay

Bristol-myers Squibb Pharma Company

Ineyte Corporation

Incyte Corportion

Prelude Therapeutics Incorporation

Andrew Paul Combs

Richard B Sparks

Eddy W Yue

Yun-Long Li

Thomas P Maduskuie, Jr

Nikoo Falahatpisheh

Stacey Shepard

Brent Douty

Lixin Shao

Andrew W Buesking

Wenyu Zhu

Artem Shvartsbart

James David Rodgers

Song Mei

Daniel Levy

David M Burns

Haisheng Wang

Ravi Kumar Jalluri

Ge Zou

Padmaja Polam

Wenqing Yao

Brian Walter Metcalf

Joseph Glenn

Yanran Ai

Jincong Zhuo

Chunhong He

Eddy Wai Tsun Yue

Thomas P Maduskuie

Liang Lu

Xiaowei Wu

Michael Jason Bower

Amy Takvorian

Jiacheng Zhou

Zhongjiang Jia

Pingli Liu

Hao Feng

Argyrios George Arvanitis

Lingkai Weng

Qiyan Lin

Rupa S Shetty

Tai-Yuen Yue

Darius J Robinson

Raul A Leal

Brian M Glass

Katarina Rohlfing

Peng Wei

Sarah Pawley

Ryan Holmes

Eddy Wai Yue

Philip Michael Pitis

Carl P Decicco

Hui-Yin Li

James Russell Pruitt

Wei Han

Andrew J Tebben

Lorin A Thompson, Iii

Juan Luengo

Hong Lin

Krishna Vaddi

Robert A Copeland

Jordan S Fridman

C Anne Higley

Susan V DiMeo

Rupa Shetty

Nilsa R Graciani

John A Rose

Klare Lazor Bersch

Danielle Julie Beam

Chaofeng Dai

Corey Howard Basch

Matthew L Crawley

Charles F Albright

Randine L Dowling

Pearl S Huang

Jialiang Wang

Heisheng Wang

Thomas P Maduskuie Jr

Jr Thomas P Maduskuie

The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.

BRM targeting compounds and associated methods of use

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

Aminopyrazine derivatives as PI3K-γ inhibitors

Aminopyrazine diol compounds as PI3K-y inhibitors

The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.

1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c] pyridin-7(6H)-ones as inhibitors of BET proteins

The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

Heterocyclylamines as PI3K inhibitors

The present invention relates to salts and crystalline forms of 2-(3-(8-Amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, and crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, which are PI3K inhibitors useful in the treatment of cancer and other diseases.

Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor

The present application provides methods of treating PI3Kδ related disorders using compounds of Formula I: or pharmaceutically acceptable salts thereof.

Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders

The disclosure is directed to compounds of Formula I pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.

CDK inhibitors and their use as pharmaceuticals

This application relates to compounds of Formula (I):

Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors

Heterocyclic derivatives as PI3K inhibitors

This application relates to derivatives of Formula I: and pharmaceutically acceptable salts thereof, which are inhibitors of PI3K, and compositions and methods of treatment related thereto.

Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors

The present disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that modulate the activity of phosphoinositide 3-kinases-gamma (PI3Kγ) and are useful in the treatment of diseases related to the activity of PI3Kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

Pyridine and pyridimine compounds as PI3K-gamma inhibitors

Aminopyrazine diol compounds as PI3K-γ inhibitors

Tertiary alcohols as PI3K-γ inhibitors

Growing community of inventors

Kennett Square, PA, United States of America

Andrew Paul Combs